SELLAS Life Sciences Group, Inc.
March 15, 2024 - by Joey Ramson
$SLS, a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications, gapped down below its 200DMA today after it announced $20 million registered direct offering and concurrent private placement. $SLS was trading in a steep uptrend since the beginning of February before todays news.
